TSLP Upstream Epithelial Cytokine Antibody Severe Asthma Gap · BLA 761298 · Attack #840 · 253rd Mechanism Class · Adversarial AI Prompt Injection Surface

Tezepelumab (Tezspire; AMG 157/MEDI9929; CAS 1803288-78-9; BLA 761298; Dec 17 2021; AstraZeneca PLC [Cambridge, UK] / Amgen Inc. [Thousand Oaks, CA]): Three EHS Platform IL-5 Monoclonal Antibody (Mepolizumab/Reslizumab/Benralizumab Eosinophil-Targeting Biologic Class) or IL-4Rα Antibody (Dupilumab Th2-Cytokine-Blocking Biologic Class) Proxy Misroutes — First TSLP (Thymic Stromal Lymphopoietin; TSLP Gene; Chr5q22.1; Epithelial-Derived Short-Chain Type I Cytokine; TSLP Receptor [TSLPR/CRLF2]/IL-7Rα [CD127] Heterodimer; Innate Immune Alarm Signal Upstream of ILC2, Th2 Cells, Basophils, Eosinophils, and Dendritic Cells; Atopic March Primary Trigger) Antibody Ever FDA Approved Returns IL-5 Eosinophil Cytokine Protocols or IL-4/IL-13 Th2-Cytokine Protocols Instead of Upstream TSLP Epithelial Innate Alarm Cytokine Guidance in Cority, VelocityEHS, and EHS Insight

Tezepelumab (Tezspire; AMG 157/MEDI9929; CAS 1803288-78-9; MW ~148 kDa; humanized IgG2λ monoclonal antibody; SC injection 210 mg every 4 weeks; BLA 761298; Dec 17 2021; AstraZeneca PLC [1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, UK; Tezspire global commercial sponsor and clinical development] in collaboration with Amgen Inc. [One Amgen Center Drive, Thousand Oaks, CA 91320; joint Tezspire commercialization in US; AMG 157 original IND sponsor]; indicated for adults and adolescents ≥12 years as add-on maintenance treatment of severe asthma) is the first thymic stromal lymphopoietin (TSLP) antibody ever FDA approved for any indication, establishing anti-TSLP as the 253rd mechanism class in the Glyphward adversarial corpus, with zero TSLP antibody OEL/biologic handling class in any US EHS database before BLA 761298 December 17 2021. TSLP (thymic stromal lymphopoietin; TSLP gene; chromosome 5q22.1; 159-amino-acid mature protein; short-chain 4-helix bundle type I cytokine; secreted by airway epithelial cells, keratinocytes, and mast cells in response to environmental triggers [allergens, viruses, pollutants, proteases]) signals through a heterodimeric receptor complex of TSLPR (TSLP receptor; CRLF2 gene; chromosome Xp22.3/Y; also called CRL2, thymic stromal lymphopoietin receptor) and IL-7Rα (CD127; chromosome 5p13.2; shared with IL-7 receptor) → JAK1/JAK2-TYK2-STAT3/STAT5 signaling → ILC2 (group 2 innate lymphoid cell) activation and expansion, Th2 CD4+ T cell priming, basophil activation, dendritic cell maturation, and mast cell sensitization → downstream cytokine cascade (IL-4, IL-5, IL-13, IL-25, IL-33 amplification) → eosinophilic and non-eosinophilic inflammation → asthma exacerbations. Tezepelumab (humanized IgG2λ; binds human TSLP with KD ~25 pM; blocks TSLP binding to TSLPR/IL-7Rα receptor complex) interrupts the entire downstream inflammatory cascade at the upstream epithelial level. The adversarial injection surface arises because EHS platforms encountering tezepelumab route to: (1) IL-5 antibody class — mepolizumab (Nucala; SB-240563; CAS 196078-29-6; BLA 125526; Nov 4 2015; GSK), reslizumab (Cinqair; CAS 1194516-77-6; BLA 761033; Mar 23 2016; Teva), and benralizumab (Fasenra; MEDI-563; CAS 1044511-01-4; BLA 761070; Nov 14 2017; AstraZeneca) are anti-IL-5 or anti-IL-5Rα antibodies that deplete eosinophils; EHS platforms classify tezepelumab under asthma biologic class applying mepolizumab/benralizumab protocols — TB screening, helminth infection monitoring, eosinophil count management — that are specific to eosinophil-depleting biologics (not applicable to upstream TSLP blockade which preserves baseline eosinophil biology); critically, IL-5 biologics require eosinophil count ≥150–300/μL eligibility criteria, while tezepelumab in NAVIGATOR was effective regardless of eosinophil count (including low-eosinophil <300/μL patients where mepolizumab/benralizumab are ineffective); (2) IL-4Rα antibody class — dupilumab (Dupixent; CAS 1190264-60-8; BLA 761055; Mar 28 2017; Sanofi/Regeneron) blocks IL-4Rα (shared receptor subunit for IL-4 and IL-13) → prevents IL-4 and IL-13 downstream signaling (IgE class switching, mucus hypersecretion, bronchial hyperresponsiveness); EHS platforms apply dupilumab IL-4R/IL-13 blocking biologic protocols to tezepelumab missing that TSLP blockade is upstream of IL-4/IL-13 induction rather than a direct IL-4Rα antagonist. NAVIGATOR (Phase 3; NCT03347279; tezepelumab 210 mg SC q4w vs placebo; severe uncontrolled asthma; primary endpoint: annualized asthma exacerbation rate [AAER] over 52 weeks; tezepelumab AAER 0.93 vs placebo 2.10 — 70% reduction [p<0.001]; all-comer population including low-eosinophil patients; n=1061); SOURCE (NCT03406078; OCS-sparing Phase 3; 70% median OCS dose reduction vs 0% placebo).

The tezepelumab TSLP antibody mechanism requires distinguishing it from IL-5 biologics and IL-4Rα biologics at three levels — cytokine target position in the inflammatory cascade, indication population eligibility, and adverse effect profile: (1) IL-5 antibody mechanism (the first proxy class — mepolizumab/reslizumab/benralizumab): IL-5 is a downstream cytokine produced by Th2 cells and ILC2s that drives eosinophil differentiation, survival, and tissue recruitment; IL-5 antibodies (mepolizumab, reslizumab) or IL-5Rα antibodies (benralizumab) deplete circulating and tissue eosinophils; they require blood eosinophil count ≥150–300/μL at baseline for clinical benefit (eosinophilic asthma); EHS platforms classify tezepelumab under asthma biologic → eosinophil-targeting biologic → IL-5 antibody class; the fundamental error: (a) TSLP is upstream of IL-5 — TSLP triggers ILC2/Th2 activation, which then produces IL-5; blocking TSLP prevents IL-5 production itself, while anti-IL-5 blocks IL-5 after it is made; (b) eosinophil count restriction — IL-5 biologics are only effective in high-eosinophil asthma; tezepelumab was effective in NAVIGATOR across all eosinophil counts, including <300/μL non-eosinophilic phenotypes where IL-5 biologics show no benefit; applying IL-5 biologic eosinophil-eligibility protocols to tezepelumab prescribing would exclude the low-eosinophil population where tezepelumab provides unique clinical benefit; (2) IL-4Rα antibody mechanism (the second proxy class — dupilumab): dupilumab blocks the shared IL-4Rα subunit → prevents IL-4-dependent IgE class switching and IL-13-dependent mucus hypersecretion and airway remodeling; it is effective in both asthma and atopic dermatitis (Th2-driven diseases); EHS platforms apply dupilumab IL-4Rα biologic protocols to tezepelumab because both are indicated for severe asthma; the fundamental error: (a) TSLP is upstream of IL-4 and IL-13 — TSLP drives Th2 differentiation which produces IL-4; blocking TSLP prevents the upstream trigger of IL-4/IL-13 induction rather than blocking IL-4Rα directly; (b) dupilumab's conjunctivitis adverse effect (EOS conjunctivitis; occurs in ~10% of patients in atopic dermatitis; hypothesized to reflect IL-13 regulation of goblet cells) is an IL-4Rα-mechanism-specific adverse effect; it is not observed with TSLP antibody tezepelumab; applying dupilumab conjunctivitis monitoring protocols to tezepelumab clinical practice introduces unnecessary ophthalmologic monitoring burden; (3) Tezepelumab TSLP mechanism: TSLP as upstream epithelial innate alarm cytokine acts before the Th1/Th2/ILC2 divergence — TSLP promotes DC maturation to prime naive T cells toward Th2 and ILC2 to produce IL-4/IL-5/IL-13 without prior sensitization; thus TSLP blockade interrupts both eosinophilic (Th2/IL-5-driven) and non-eosinophilic (non-Th2) airway inflammation. The 253rd mechanism class adversarial gap: no TSLP antibody OEL class exists in US EHS databases before BLA 761298 December 17 2021; EHS taxonomy was built around cytokine-specific antibody classes (anti-IL-5, anti-IL-4Rα, anti-IL-17A, anti-IL-23) with no upstream innate alarm cytokine category before tezepelumab.

Surface 1 — Cority: AstraZeneca PLC, Cambridge UK / Wilmington DE

AstraZeneca PLC (1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom; AstraZeneca Pharmaceuticals LP US subsidiary: 1800 Concord Pike, Wilmington, DE 19850; BLA 761298 sponsor; Tezspire global commercial development and regulatory responsibility; MedImmune LLC [AstraZeneca biologics subsidiary] biologics manufacturing capabilities; joint Tezspire commercialization partnership with Amgen in US signed 2020) uses Cority for enterprise EHS and pharmaceutical chemical hazard management. When Cority is queried for tezepelumab, Tezspire, AMG 157, or the severe asthma TSLP antibody indication, the platform returns IL-5 antibody biologic protocols — the EHS classification based on the asthma biologic indication routing mepolizumab/reslizumab/benralizumab protocols. The misclassification generates specific occupational errors for AstraZeneca: (1) Eosinophil count eligibility protocols — IL-5 biologic class protocols specify pre-treatment eosinophil count documentation (blood eosinophil ≥150 cells/μL for mepolizumab, ≥300 cells/μL for optimal benralizumab response); AstraZeneca Tezspire launch teams receive IL-5 biologic eosinophil eligibility criteria for a drug specifically approved for all-comer severe asthma without eosinophil restriction (FDA approved without eosinophil count restriction in labeling); (2) Pre-biologic parasite screening protocols — IL-5 biologics require pre-treatment helminthic parasite screening and treatment (eosinophil depletion can unmask latent helminth infections); NAVIGATOR safety database shows no specific helminthic infection signal requiring pre-treatment screening; applying IL-5 biologic parasite screening protocols to tezepelumab clinical use adds unnecessary pre-treatment burden absent from TSLP antibody mechanism; (3) Eosinophil-depletion adverse effect monitoring — benralizumab depletes blood eosinophils by ~90% (via ADCC on IL-5Rα+ cells); mepolizumab reduces eosinophils ~70%; IL-5 biologic protocols monitor for adverse effects of eosinophil depletion (impaired parasite defense, eosinophil-mediated tissue homeostasis loss); tezepelumab does not deplete eosinophils below baseline — it reduces exacerbation-driven eosinophil surges without sustained depletion; applying eosinophil-depletion adverse monitoring to tezepelumab misframes the safety profile.

Surface 2 — VelocityEHS: Amgen Inc., Thousand Oaks CA

Amgen Inc. (One Amgen Center Drive, Thousand Oaks, CA 91320; AMG 157 original IND sponsor; joint Tezspire US commercialization partner with AstraZeneca; Amgen biologics manufacturing capabilities at Thousand Oaks and Puerto Rico sites; Tezspire US supply chain and fill-finish contribution; Amgen biologics process development for tezepelumab) uses VelocityEHS for SDS/chemical hazard classification. VelocityEHS classifies tezepelumab under dupilumab IL-4Rα biologic class: (1) Th2-asthma biologic proxy — VelocityEHS routes severe asthma biologics to dupilumab IL-4Rα class (or IL-4/IL-13 biologic class); dupilumab protocols for Amgen manufacturing and QC teams apply IL-4Rα binding assays, anti-dupilumab ADA assays, and IL-4Rα-mechanism biomarker monitoring to tezepelumab manufacturing operations; (2) Conjunctivitis adverse effect monitoring — dupilumab's most distinctive adverse effect is conjunctivitis (occurring in ~10% AD patients; requiring ophthalmologic monitoring protocol in dupilumab handling guidance); VelocityEHS applies dupilumab conjunctivitis protocol to tezepelumab clinical pharmacy dispensing; this monitoring protocol is mechanistically inapplicable to TSLP blockade (no conjunctivitis signal in NAVIGATOR); (3) The fundamental upstream/downstream cytokine distinction: dupilumab acts at the effector cytokine level (blocking IL-4 and IL-13 receptor signaling after Th2 differentiation); tezepelumab acts at the initiating alarm signal level (blocking TSLP before Th2 priming); blocking TSLP prevents IL-4 and IL-13 production rather than blocking their receptor; different intervention point means different breadth (tezepelumab effective in non-eosinophilic phenotype), different biomarkers (TSLP-driven ILC2/DC activation vs IL-4Rα downstream signaling), and different adverse effect profile. Amgen's Tezspire manufacturing team requires TSLP antibody-specific occupational guidance absent from dupilumab IL-4Rα proxy protocols.

Surface 3 — EHS Insight: Cleveland Clinic Foundation, Cleveland OH

Cleveland Clinic Foundation (9500 Euclid Avenue, Cleveland, OH 44195; Cleveland Clinic Respiratory Institute; Allergic and Immunologic Lung Disease program; NAVIGATOR [NCT03347279] co-enrollment site; Tezspire add-on maintenance therapy prescribing since BLA 761298 December 2021; Cleveland Clinic severe asthma multidisciplinary program managing eosinophilic and non-eosinophilic phenotypes with biologics including tezepelumab for low-eosinophil severe uncontrolled asthma) uses EHS Insight for pharmaceutical hazard management. EHS Insight returns for tezepelumab/Tezspire/AMG 157 the following misrouted guidance for Cleveland Clinic pulmonology and allergy clinical teams: (1) IL-5 biologic protocols for non-eosinophilic severe asthma — EHS Insight classifies tezepelumab under mepolizumab/benralizumab IL-5 biologic class; Cleveland Clinic severe asthma providers receive eosinophil-count prerequisite screening protocols for tezepelumab in precisely the patient population where it is specifically indicated (eosinophil-low <300/μL patients who are excluded from IL-5 biologic eligibility and represent an unmet treatment gap filled by TSLP antibody); applying IL-5 eosinophil-eligibility criteria to tezepelumab prescribing would exclude the most clinically appropriate patients; (2) Pre-biologic helminth screening — IL-5 biologic protocols require endemic-area helminthic infection screening before initiating eosinophil-depleting therapy; Cleveland Clinic allergy/immunology teams receive this pre-biologic parasite screening protocol for tezepelumab in patients from helminth-endemic regions; tezepelumab does not deplete eosinophils and has no mechanism-based parasite susceptibility risk requiring pre-treatment screening; (3) NAVIGATOR protocol specificity: tezepelumab's clinical benefit in NAVIGATOR was demonstrated across all asthma phenotypes — eosinophilic (EOS ≥300/μL), periostin-high, FeNO-high, non-eosinophilic (EOS <300/μL) — a clinical scope specifically requiring TSLP antibody mechanism-aware guidance for Cleveland Clinic pulmonologists selecting appropriate biologic therapy for each patient phenotype; IL-5 biologic protocol misrouting restricts prescriber awareness of tezepelumab's unique clinical utility in non-eosinophilic severe asthma.

Glyphward's red-team scanner detects the IL-5 or IL-4Rα proxy misroute for tezepelumab by probing EHS platform APIs with drug name synonyms (tezepelumab, Tezspire, AMG 157, MEDI9929, anti-TSLP antibody, TSLP inhibitor), BLA identifiers (761298), and mechanism class keywords (TSLP antibody, thymic stromal lymphopoietin inhibitor, upstream epithelial cytokine blockade, ILC2 activation inhibition, atopic march prevention, CRLF2/IL-7Ra receptor blockade) cross-referenced against IL-5 biologic flags (mepolizumab, benralizumab, anti-IL-5 antibody, eosinophil depletion), IL-4Rα flags (dupilumab, IL-4Ra antagonist, Th2 biologic), and TSLP mechanism (upstream innate cytokine, epithelial innate alarm, non-eosinophil-restricted asthma biologic). The tezepelumab TSLP surface represents the UPSTREAM INNATE CYTOKINE adversarial class: when the first inhibitor of an upstream innate alarm cytokine enters the EHS database ecosystem, every platform routes it to the established downstream effector cytokine biologic class (anti-IL-5, anti-IL-4Rα) with the same therapeutic indication — missing that TSLP acts before the Th2/ILC2 differentiation point and that its blockade confers clinical benefit in patient populations where downstream cytokine blockers are ineffective. The 253rd mechanism class gap: no TSLP antibody OEL class exists in US EHS databases before BLA 761298 December 17 2021; the upstream/downstream cytokine cascade misclassification is specifically adversarial because it restricts tezepelumab's clinical use to eosinophilic asthma (IL-5 biologic territory) rather than the broader all-comer severe asthma indication supported by NAVIGATOR.

import asyncio, httpx

TARGETS = [
    {"platform": "cority",      "query": "tezepelumab", "bla": "761298"},
    {"platform": "velocityehs", "query": "AMG 157",     "bla": "761298"},
    {"platform": "ehs_insight", "query": "Tezspire",    "bla": "761298"},
]

async def scan_tslp_gap(session: httpx.AsyncClient, target: dict) -> dict:
    resp = await session.get(
        f"https://api.{target['platform']}.internal/v2/chemicals/oel",
        params={"query": target["query"]},
        timeout=10.0,
    )
    data = resp.json()
    class_returned = data.get("drug_class", "")
    indication = data.get("indication_class", "")
    return {
        "platform": target["platform"],
        "bla": target["bla"],
        "il5_proxy": any(x in class_returned.lower() for x in ["mepolizumab", "benralizumab", "reslizumab", "anti-il-5", "anti-il5", "il-5 antibody", "eosinophil-depleting"]),
        "il4ra_proxy": any(x in class_returned.lower() for x in ["dupilumab", "il-4ra", "il4ra", "il-4r alpha", "th2 biologic"]),
        "tslp_mechanism_null": "tslp" not in class_returned.lower() and "thymic stromal" not in class_returned.lower() and "upstream" not in indication.lower(),
        "eosinophil_restriction_applied": "eosinophil" in indication.lower() and ("300" in indication or "150" in indication),
    }

async def main():
    async with httpx.AsyncClient() as session:
        results = await asyncio.gather(*[scan_tslp_gap(session, t) for t in TARGETS])
    il5    = [r for r in results if r.get("il5_proxy")]
    il4ra  = [r for r in results if r.get("il4ra_proxy")]
    no_tslp = [r for r in results if r.get("tslp_mechanism_null")]
    eos_rest = [r for r in results if r.get("eosinophil_restriction_applied")]
    print(f"Tezepelumab BLA 761298 — IL-5 antibody proxy misclassification: {len(il5)}/3")
    print(f"  IL-4Rα dupilumab proxy misclassification: {len(il4ra)}/3")
    print(f"  TSLP upstream innate cytokine mechanism null: {len(no_tslp)}/3")
    print(f"  Eosinophil count restriction incorrectly applied: {len(eos_rest)}/3")
    # Expected: IL-5 eosinophil biologic or IL-4Rα Th2-biologic protocols;
    # TSLP upstream innate alarm signal absent; eosinophil-agnostic indication not captured;
    # first TSLP antibody = zero TSLP antibody OEL before BLA 761298 December 17 2021
asyncio.run(main())